Rheumatoid Arthritis Drugs Market Size (2024 - 2029)

Rheumatoid Arthritis Drugs Market Analysis

The Rheumatoid Arthritis Drugs Market size is estimated at USD 56.55 billion in 2024, and is expected to reach USD 75.26 billion by 2029, growing at a CAGR of 5.88% during the forecast period (2024-2029).

The key factors propelling the growth of the rheumatoid arthritis drugs market are the launch of new biosimilars, the rising prevalence of arthritis across the world, and the acceptance of biopharmaceuticals. Various factors, such as increasing age and lifestyle changes, are expected to raise the risk for rheumatoid arthritis, which is expected to drive the market growth over the study period. For instance, according to the data published by the National Center for Health Statistics in February 2024, the prevalence of arthritis was found to be directly proportional to the rising age across the world, rising from 3.6% in adults aged 18–34 to 53.9% in individuals aged 75 and older. This scenario may lead to increased adoption of therapies for rheumatoid arthritis treatment and thus drive the market’s growth.

The rising burden of rheumatoid arthritis in various age groups is expected to increase the need for its drug treatment, boosting the market growth. For instance, as per the data published by Statistique Canada in November 2023, the number of people aged 12 years and over in Canada with arthritis was reported to be 6.28 million in 2022, compared to 6.08 million in the previous year. Hence, the growing prevalence of arthritis among the population may increase the demand for arthritis drugs, which may drive the market growth over the forecast period.

Additionally, rising launches of biosimilars for treating rheumatoid arthritis may also contribute to market growth. For instance, in October 2023, Pfizer Inc. secured an interchangeable biosimilar designation for ABRILADA (adalimumab-afzb) from the US Food and Drug Administration (FDA). This interchangeable designation encompasses all approved indications of ABRILADA, which include specific patients with rheumatoid arthritis (RA). Similarly, in July 2023, Coherus BioSciences Inc. launched YUSIMRY (adalimumab-aqvh) for commercial sale in the United States. It is one of the biosimilars to Humira in treating rheumatoid arthritis. Hence, affordable rheumatoid arthritis treatments are anticipated to witness demand in the coming years.

Thus, owing to the abovementioned factors, such as the rising burden of rheumatoid arthritis and new product launches, the market is expected to grow over the forecast period. However, alternative treatment options and the expiration of the patents of branded drugs may hinder the market's growth during the forecast period.

Rheumatoid Arthritis Drugs Industry Segmentation

Rheumatoid arthritis is an autoimmune disorder that causes pain and inflammation in the body's joints. It primarily affects the joints of the hands, wrists, elbows, knees, and ankles. It also affects the cardiac and respiratory systems and is a systemic disease. It thus exhibits symptoms of swelling, redness, and warmth in the affected areas. The drugs to treat rheumatoid arthritis include NSAIDs, corticosteroids, DMARDs, biologics, and analgesics, which help reduce inflammation, suppress the immune system, and relieve pain.

The rheumatoid arthritis drugs market is segmented by type of molecule, drug class, sales channel, and geography. By type of molecule, the market is segmented into pharmaceuticals and biopharmaceuticals. By drug class, the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), disease-modifying antirheumatic drugs (DMARDs), corticosteroids, analgesics, and other drug classes. By sales channel, the market is segmented into prescription and over-the-counter (OTC). By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across significant global regions. The report offers market sizes and forecasts in terms of value (USD) for the above segments.